ACAD - ACADIA Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ACAD is currently covered by 24 analysts with an average price target of $24.86. This is a potential upside of $6.97 (38.96%) from yesterday's end of day stock price of $17.89.

ACADIA Pharmaceuticals's activity chart (see below) currently has 316 price targets and 283 ratings on display. The stock rating distribution of ACAD is 33.33% HOLD, 65.63% BUY and 1.04% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 65.9% with an average time for these price targets to be met of 211.28 days.

Highest price target for ACAD is $42, Lowest price target is $19, average price target is $24.86.

Most recent stock forecast was given by YATIN SUNEJA from GUGGENHEIM on 03-Jan-2025. First documented stock forecast 06-May-2013.

Currently out of the existing stock ratings of ACAD, 32 are a HOLD (33.33%), 63 are a BUY (65.63%), 1 are a SELL (1.04%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$20

$2.43 (13.83%)

$25

18 days ago
(03-Jan-2025)

4/6 (66.67%)

$1.31 (7.01%)

204

Buy

$27

$9.43 (53.67%)

$27

2 months 14 days ago
(07-Nov-2024)

8/22 (36.36%)

$9.79 (56.89%)

119

Buy

$28

$10.43 (59.36%)

$28

2 months 14 days ago
(07-Nov-2024)

0/4 (0%)

$10.79 (62.70%)

Hold

3 months 11 days ago
(10-Oct-2024)

11/14 (78.57%)

$9.98 (39.89%)

141

Buy

$23

$5.43 (30.90%)

$30

5 months 13 days ago
(08-Aug-2024)

0/3 (0%)

$7.28 (46.31%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ACAD (ACADIA Pharmaceuticals) average time for price targets to be met?

On average it took 211.28 days on average for the stock forecasts to be realized with a an average price target met ratio 65.9

Which analyst has the current highest performing score on ACAD (ACADIA Pharmaceuticals) with a proven track record?

CORY KASIMOV

Which analyst has the most public recommendations on ACAD (ACADIA Pharmaceuticals)?

Cory Kasimov works at EVERCORE and has 5 price targets and 3 ratings on ACAD

Which analyst is the currently most bullish on ACAD (ACADIA Pharmaceuticals)?

Alan Carr with highest potential upside - $42.43

Which analyst is the currently most reserved on ACAD (ACADIA Pharmaceuticals)?

Salveen Richter with lowest potential downside - -$5.57

ACADIA Pharmaceuticals in the News

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

Company to host conference call and webcast on Wednesday, November 6, 2024, at 4:30 p.m. Eastern Time SAN DIEGO, October 17, 2024–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Acadia’s management team will also...

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome

— DAYBUE is the first and only therapy approved in Canada for the treatment of Rett syndrome, a rare, neurodevelopmental disorder SAN DIEGO, October 16, 2024–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?